---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-25-000060"
form_type: "8-K/A"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:47:14.344592+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs doses first volunteers in Phase 1 trial of SL-325; closes $103M private placement

## Summary
- First participants dosed in Phase 1 trial of SL-325, a DR3 antagonist antibody, in healthy volunteers.
- Closed private placement of up to $103M in August 2025; cash expected to fund operations into 2029.
- Net loss of $10.1M ($0.14 per share) vs $16.6M ($0.33) in Q3 2024; R&D expenses down to $7.6M.
- Cash and investments at $86.1M as of Sep 30, 2025, supporting pipeline advancement.

## SEC filing metadata
- accession: 0001680367-25-000060
- form_type: 8-K/A
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036725000060/0001680367-25-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036725000060/sttk-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-25-000060
- JSON: https://secwatch.observer/filing/0001680367-25-000060.json
- Plain text: https://secwatch.observer/filing/0001680367-25-000060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.